Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 

NSC_logoThe cost of publication in Journal of Biomedical Science is borne by the National Science Council, Taiwan.

Open AccessResearch

Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice

Giou-Teng Yiang1,2* email, Horng-Jyh Harn3* email, Yung-Luen Yu4,5* email, Sheng-Chuan Hu1,2 email, Yu-Ting Hung6 email, Chia-Jung Hsieh6 email, Shinn-Zong Lin7 email and Chyou-Wei Wei6 email

Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan

Department of Emergency Medicine, Tzu Chi General Hospital, Hualien, Taiwan

Department of Pathology, China Medical University Hospital, Taichung, Taiwan

Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University and Hospital, Taichung, Taiwan

Department of Biotechnology, Asia University, Taichung, Taiwan

Institute of Biomedical Nutrition, College of Medicine & Nursing, Hung Kuang University, Sha Lu, Taichung, Taiwan

Department of Neurosurgery, China Medical University Hospital, Taichung, Taiwan

author email corresponding author email* Contributed equally

Journal of Biomedical Science 2009, 16:47doi:10.1186/1423-0127-16-47

Published: 7 May 2009

Abstract

Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human cancer gene therapy.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.